




*Giornate Catanesi di Nutrizione Clinica*  
10|11 Maggio 2019

«LA NUTRIZIONE E LA MALATTIA»

# Farmaconutrizione nel paziente geriatrico immunodepresso

Pietro Vecchiarelli




# What is Aging?



Complex transition that includes a physiological and cognitive vulnerability making the individual more prone to diseases and acute medical events, leading to further decrease in reserve capacities of functional independence and ultimately to death

# Immune-inflammatory responses in the elderly: an update

Giulia Accardi<sup>1,2</sup> and Calogero Caruso<sup>1,2\*</sup>



**Immunosenescence:** age related **decline in immune function** at the cellular and serological level.

These changes lead to poor response to newly encountered microbial antigens, including vaccines, as well as to shift of the immune system towards **an inflammatory, autoimmune profile**.

This immune dysregulation provides the background for an increased susceptibility to autoimmune diseases, cancer, metabolic diseases, osteoporosis, neurological disorders, as well as allergic inflammation and infections.



## Sicilian centenarian offspring are more resistant to immune ageing

Graziella Rubino<sup>1,2</sup> · Matteo Bulati<sup>2</sup> · Anna Aiello<sup>2</sup> · Stefano Aprile<sup>2</sup> · Caterina Maria Gambino<sup>2</sup> · Francesco Gervasi<sup>3</sup> · Calogero Caruso<sup>2</sup> · Giulia Accardi<sup>2</sup>

Received: 8 January 2018 / Accepted: 21 March 2018

© Springer International Publishing AG, part of Springer Nature 2018

The whole present data confirm and extend the previous results showing that centenarian offspring retain more youthful immunological parameters and that the exhaustion of the immune system is less evident than in elderly without centenarian parents [15, 39–43].

## Innate Immune Cells

---


## Age-Associated Changes

Neutrophils



- Decreased phagocytosis
- Decreased chemotaxis
- Defective apoptosis function

Macrophages



- Decreased antigen presentation
- Decreased superoxide anion production
- Defective phagocytosis
- Decreased cytokine production

NK cells




- Reduced cytolytic potential
- Decreased cytokine and chemokine production
- Reduced CD1 expression in NKT cells

## Bridging innate and adaptive immunity

---

DC




- Reduced IFN production
- Reduced expression of CD25 and ICAM-1 in mature MODCs
- Reduction in lymphocyte cytotoxicity and greater migratory capacity of monocyte-macrophage derived APCs.

## Adaptive Immune Cells


---

T Cells



- Reduced development (Thymus atrophy). Reduced numbers of naïve CD4<sup>+</sup>/CD8<sup>+</sup> T cells, and increased number of effector and memory CD4<sup>+</sup>/CD8<sup>+</sup> T cells
- Decline in CD8<sup>+</sup> T cell cytotoxicity and proliferation
- Decline in CD4<sup>+</sup> function, less generation of Th subsets (Th1 and Th2)


B cells



- Reduced development. Reduced number of naïve B cells
- Decrease in B cell responses to new antigens
- Decreased diversity of B cell repertoires in elderly subjects



# Effect of age on the production and distribution of lymphocytes



# INFLAMM-AGING

Chronic, sterile, subclinical , low grade inflammation related to the ageing, produced as consequence of:

- Dysfunctional mitochondria;
- Defective autophagy;
- Endoplasmic reticulum stress;
- Activation of inflammasome by cells debris;
- Defective ubiquitin/proteasome system;
- Activation of DNA damage response;
- Senescent T cells;
- Age-related changes in the composition of microbiota (dysbiosis)



# Expansion of myeloid-derived suppressor cells with aging in the bone marrow of mice through a NF- $\kappa$ B-dependent mechanism

Flores R et al. Aging Cell 2017

Although it has been demonstrated that the percent of MDSC as well as MDSC with NF- $\kappa$ B activation increases with accelerated and natural aging, the role of the MDSC, if any, in the aging process is unclear. It is also unclear whether the expansion of MDSCs drives aging or only is a consequence of aging. However, given that MDSCs accumulate in the spleen, peripheral lymph nodes, bone marrow, and blood of normal aged mice and are significantly increased in the circulation of aged individuals, it is likely that MDSCs contribute to age-associated immune dysfunction. Similarly, the increase in MDSCs with aging could contribute to the increased risk of cancer.



# Role of MDSCs




IMC= Immature Myeloid Cells


MDSCs= Myeloid Derived Suppressor Cells

SASP= Senescence Associated Secretory Phenotype


# The host response to infection




# The development of persistent inflammation and immunosuppression



# The divergent yet similar pathways to develop PICS




# Phases of critical illness: a guess!



<b>Acute phase</b>				
	<b>Organ dysfunction</b>	<b>Inflammation</b>	<b>Metabolic status</b>	<b>Days</b>
<b>Early</b>	Severe/progressive	<b>Progressive</b>	<b>Catabolic</b>	1-3
<b>Late</b>	Stable/regressive	<b>Persistent/Regressive</b>	<b>Catabolic-Anabolic</b>	2-4
<b>Post acute phase</b>				
<b>Recovery</b>	Reconstitution	Resolution of inflammation	Anabolic	> 7
<b>Chronic</b>	Persistent	<b>Persistent Inflammation &amp; Immunosuppression</b>	<b>Catabolic</b>	> 7



# The new paradigm of Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS)



# Markers used to identify patients with/or a risk of PICS


<b>PICS</b>	<b>Measurement</b>
Critically ill patient	Admission to the ICU >14 d
Persistent inflammation	CRP >50 $\mu\text{g/dL}$
Persistent immunosuppression	Total lymphocyte count $<0.80 \times 10^9/\text{L}$
Catabolic state	Serum albumin $<3.0 \text{ g/dL}$ Prealbumin $<10 \text{ mg/dL}$ Creatinine height index $<80\%$ Weight loss $>10\%$ or BMI $<18$ during hospitalization



# Very old patients admitted to intensive care in Australia and New Zealand: a multi-centre cohort analysis

Sean M Bagshaw<sup>1,2</sup>, Steve AR Webb<sup>3,4</sup>, Anthony Delaney<sup>5</sup>, Carol George<sup>6</sup>, David Pilcher<sup>7</sup>, Graeme K Hart<sup>1</sup> and Rinaldo Bellomo<sup>8</sup>


**Table 1**  
**Summary of patient demographics, admission details and primary diagnoses by age strata**



# Mortality rates in elderly patients at ICU and hospital discharge


**a**

Prospective singlecenter studies (n=1466 patients)




**b**

Prospective multicenter studies (n=7376 patients)



# Can we interrupt this vicious cycle?





# Farmaco-Nutrition



Proteins

Micronutrients

Vitamines

Aminoacids

Fatty Acids

Probiotics

Symbiotics

Antioxidants

Prebiotics

Nucleotides

## **Vitamin E ingestion improves several immune functions in elderly men and women**

*Free Radical Research, March 2008; 42(3): 272–280*

MONICA DE LA FUENTE<sup>1</sup>, ANGEL HERNANZ<sup>2</sup>, NOELIA GUAYERBAS<sup>1</sup>,  
VICTOR MANUEL VICTOR<sup>1</sup>, & FRANCISCO ARNALICH<sup>3</sup>

- ✓ Contained in the membranes of the immune cells
- ✓ Strong antioxidant
- ✓ Enhance immune response + cell mediated immunity
- ✓ Increases resistance to respiratory infections in nursing home residents
- ✓ Dose: 200 mg daily for 3 months is an optimal dose for improving T cell mediate functions in the elderly

# ZINC



- ✓ Zinc deficiency affects multiple immune cells involved in both innate and adaptive immunity;
- ✓ The elderly often have a low serum Zinc level ( inadequate intake, impaired metabolism, infection, inflammation...);
- ✓ Evidence from the literature indicates that the elderly might benefit from optimizing serum Zinc level through adequate intake;
- ✓ So far optimal Zinc intake is unknown;

Cossack 1989; Prasad 2003 and 2006; Bao 2003	45 mg of zinc/day for 6 months (zinc sulfonate)
Fortes 1998	25 mg/day for 3 months (Zinc sulfate)
Kahmann 2006; Metz 2007	10 mg of pure zinc (50 mg zinc-aspartate) per day for 48 days

# Immunosenescence and nutrition: reviewing clinical evidence on pre-, pro- and synbiotics in aging

Renata Ramalho<sup>1,2,3\*</sup>

*J Allergy Immunol*, 2017

Study / Reference	Design and Participants	Intervention	Outcomes	Results
<i>Probiotics</i>				
	• Randomized, placebo-			• Increase in NK cell activity, reduction

The evidence is scarce with reduced number of studies and including small group of participants...heterogeneity in design and type of interventions is an important limitation.


Despite this limitation, it seems that pre-, probiotics and synbiotics may represent a nutritional modulation for immunosenescence.

<i>Synbiotics</i>				
Macfarlane <i>et al.</i> , 2013 [116]	<ul style="list-style-type: none"> <li>• Randomized, placebo-controlled, double-blinded cross-over study</li> <li>• 43 volunteers (22 females), 65-83 years-old</li> </ul>	<ul style="list-style-type: none"> <li>• 1 gelatin capsule <i>B. longum</i> (2x10<sup>11</sup>CFU)+6g Synergy I (Inulin+Oligofructose) twice a day for 2 weeks</li> <li>• Placebo: 1 capsule potato starch+6g Maltodextrose twice a day for 2 weeks</li> </ul>	<ul style="list-style-type: none"> <li>• Faecal microbiota</li> <li>• Inflammatory markers</li> <li>• Biochemical profiles</li> </ul>	<ul style="list-style-type: none"> <li>• Increase in number of faecal bifidobacteria (<i>Actinobacteria</i> and <i>Firmicutes</i>).</li> <li>• Reduction in faecal <i>Protoobacteria</i>.</li> <li>• Reduction in TNF-<math>\alpha</math>.</li> </ul>
Ouwehand <i>et al.</i> , 2009 [117]	<ul style="list-style-type: none"> <li>• Randomized, placebo-controlled, double-blinded parallel study</li> <li>• 47 volunteers (35 females), &gt; 65 years-old</li> </ul>	<ul style="list-style-type: none"> <li>• 1 sachet (5-5.5g) <i>L. acidophilus</i> NCFM (2x10<sup>9</sup>CFU)+Lactilol twice a day for 2 weeks</li> <li>• Placebo: 1 sachet (5g) Sucrose twice a day for 2 weeks</li> </ul>	<ul style="list-style-type: none"> <li>• Faecal microbiota</li> <li>• Mucosal immunity</li> <li>• SCFA production</li> </ul>	<ul style="list-style-type: none"> <li>• Increase in number of faecal <i>Bifidobacterium</i></li> <li>• Increase in spermidine levels</li> <li>• Modest increase in PGE2 concentration in faeces</li> </ul>

# What is the role of $\omega$ -3 in inflammation?




**Fig. 1.** Possible mechanisms of omega-3 PUFA's anti-inflammatory actions. Omega-3 PUFAs are widely held to act via several possible mechanisms, such as preventing conversion of arachidonic acid (AA) into proinflammatory eicosanoids such as 4-series LTs and 2-series PGs via substrate competition, or serving as an alternative substrate to produce less potent 5-series LTs and 3-series PGs and thromboxanes. In addition, EPA and DHA are converted to bioactive metabolites such as resolvins and protectins with anti-inflammatory and pro-resolving properties.



Courtesy of M.Muscaritoli ( modified)



# Effetto degli $\omega$ -3 sulla risposta infiammatoria






- senza aggiunta di acidi grassi  $\omega$ -3 da olio di pesce
- con aggiunta di acidi grassi  $\omega$ -3 da olio di pesce

**SIRS:** Sindrome da Risposta Infiammatoria Sistemica;  
**CARS:** Risposta Compensatoria Antinfiammatoria

# Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men<sup>1-3</sup>

Dinka Rees et al

*Am J Clin Nutr* 2006;83:331-42.



## Conclusions

- The elderly can handle dietary long-chain-n-3 PUFAs in different way;
- The host innate immune functions remained unaffected in the elderly even with high intake of long-chain -n3 PUFAs ( 4.05 g EPA+0.9 g DHA/d);
- However at this intake, neutrophil superoxide production in response to E.Coli may be impaired by to 20%;
- An intake of 1.35 g EPA+0.3 gr DHA/d does not affect innate immune function in young or in the elderly

# Fatty acids and the elderly




Cellular fatty acids impact on gene expression and act as precursors of prostaglandins, leukotriens, lipoxins and resolvins

Pae 2012	long chain <i>n</i> -3 PUFA (polyunsaturated fatty acids)	Improve cardiovascular, degenerative neurological, inflammatory and autoimmune diseases
Galli 2009; Calder 2010	<i>n</i> -3 PUFA	Anti-inflammatory properties: inhibition formation of eicosanoids (Thromboxan A2) required for platelet aggregation; inhibition of proinflammatory cytokines IL-1 $\beta$ , TNF $\alpha$ , and IL-6. Reduction of IL-8, MCP-1, ROS, NOS and adhesion molecules (ICAM-1, VCAM-1 and selectins)
Meydani 1991	<i>n</i> -3 PUFA (1.68 g EPA and 0.72 g DHA/day) for 3 months	Reduction in cytokine production, inhibition in mitogen-induced PBMC proliferation
Bechoua 2003	low doses of PUFA (30 mg EPA and 150 mg DHA/day) for 6 weeks	Decrease in lymphocyte proliferation in response to mitogens. Reduction in the glutathione activity
Bouwens 2009 and 2010	high doses of EPA (1.8 g) and DHA (1.8 g) equivalent to ten portions of oily fish per week for 26 weeks	Decrease plasma levels of free fatty acids and triglycerides, reduction in proinflammatory genes including NF- $\kappa$ B target genes, proinflammatory cytokines and genes involved in eicosanoid synthesis

# Immunonutrizione

Miscele nutrizionali arricchite con specifici nutrienti attivi sul sistema immunitario, sul metabolismo e sulla struttura e funzione del tratto gastrointestinale.




# Diète arricchite con immunonutrienti

	<b>Impact® Nestlé</b>	<b>Perative® Abbott</b>	<b>Stresson® Nutricia</b>		<b>AlitraQ® Abbott</b>
Protéines % (g·L <sup>-1</sup> )	22 % (56)	20,5 % (66,6)	24 % (75)		21 % ( 52,5)
Glutamine (g·L <sup>-1</sup> )	0	0			15,5
Arginine (g·L <sup>-1</sup> )	13.0	6,5	6,7		4,5
Nucléotides (g·L <sup>-1</sup> )	1.0	0	0		0
Lipides % (g·L <sup>-1</sup> )	25 % (28)	25 % (37,4)	30 % (42)		13 % (15,5)
n-3 (g·L <sup>-1</sup> )	1,7	1,6	30 mg		0
Antioxydants	C, E, βcarotène, zn, se	A, C, βcarotène, zn, se	éléments-traces, A, C, E,		0
Taurine (mg·L <sup>-1</sup> )	0		0		oui
kcal·mL <sup>-1</sup>	1		1		1
Osmolalité (mOsm·L <sup>-1</sup> )	375	385	420		575




# ARG e funzione immunologica

Aminoacido semiessenziale  
necessario per:



- Proliferaazione dei linfociti (Etron et al. 1991)
- Induzione delle funzioni dei T-linfociti (Etron e Barbul, 1998)
- Sintesi di NO (Nathan e Xle, 1994, Albina 1996)
- Aumento della fagocitosi PMN (Etron e Barbul, 1998)
- Aumento dell'attività delle cellule *Natural killer* (Etron e Barbul, 1998)

# RNA



- Substrato essenziale per la replicazione, la maturazione e la differenziazione cellulare (cellule a rapido turnover: linfociti, Natural Killers, enterociti, macrofagi, che non sono in grado di sintetizzare l'RNA)
- Implicato nella sintesi dei recettori dell'IL-2 e dei macrofagi
- Substrato per la sintesi proteica
- Substrato per il metabolismo e l'energia cellulare (coenzimi: NAD, FAD, ATP, etc..)

Grimble GK, 2001, Hardy G, 2002

## ARGININE / N-3 FATTY ACIDS INTERACTION

- ✓ Postoperative acquired arginine-deficient state which leads to substantial immune dysfunction
- ✓ Immature myeloid-derived suppressor cells accumulation early after surgery which express Arginase 1 (arginine depleting enzyme)
- ✓ N-3 fatty acids can blunt upregulation of immature cells and Arginase 1
- ✓ Arginine plus Omega-3 supplementation restores T-lymphocyte function including IL-2 production

# GLUTAMINE enteral supplementation

John C. Hall  
Geoffrey Dobb  
Jane Hall  
Ruth de Sousa  
Lisa Brennan  
Rosalie McCauley

## **A prospective randomized trial of enteral glutamine in critical illness**

**OBJECTIVE:** To assess the influence of enteral glutamine on the incidence of severe sepsis and death in critically ill patients.

**DESIGN:** This two-armed clinical trial was triple blind (patients, attending staff, research nurse).

**SETTING:** The 10 bed general ICU at Royal Perth Hospital, Western Australia.

**PATIENTS:** This trial evaluated 363 patients requiring mechanical ventilation (median APACHE II score=14); of these, 85 had trauma.

**INTERVENTION:** The intervention solution contained 20 g/l glutamine and the control solution was isojoulic and isonitrogenous.

**CONCLUSION:** This clinical trial did not support the use of enteral glutamine supplements in similar cohorts of critically ill patients.

## REDOXs: Important Answers, Many More Questions Raised!

Jean-Charles Preiser, MD, PhD<sup>1</sup>; and Jan Wernerman, MD, PhD<sup>2</sup>

Journal of Parenteral and Enteral Nutrition  
Volume 37 Number 5  
September 2013 566–567  
© 2013 American Society  
for Parenteral and Enteral Nutrition  
DOI: 10.1177/0148607113495893  
jpen.sagepub.com  
hosted at  
online.sagepub.com  


5. A broader unsolved issue is this: Which outcome should we use in the field of (pharmaco)nutrition? In a perfect world, we would select an outcome variable that will be meaningful (ie, an outcome directly influenced by the tested intervention), clinically relevant, and easily measurable. The survival rate is easily measurable and relevant, but how strong is the potential relation with a pharmaconutrient, especially when its mechanism of action is unknown? The infection rate is clearly relevant, and relatively easy to measure, but how can it be directly related to a pharmaconutrient that will influence much more systems than immunity?

In terms of plausibility between glutamine supplementation and these outcome variable, we are left with several different options because of the lack of knowledge of the presumably beneficial mechanism. In general terms, the adequacy of (pharmaco)nutrition could be more precisely reflected by muscle mass or strength and/or functional autonomy, than by crude variables such as mortality or length of stay.

These questions clearly demonstrate that clinical research in nutrition remains in its infancy, at least in the field of critical care medicine. To expand our previous commentary, our cur-

**2003: “Glutamine, a Life-Saving Nutrient, But Why?”**



**2013: “Glutamine, a Potentially Toxic Nutrient, But Why, How, When, and in Which Patients?”**

# Perioperative Immunonutrition



(cancer patients)

Braga M. et al. Arch Surg, 1999

206 patients (colon, stomach, pancreas) randomized trial  
Impact® or standard formula for 7 days preoperative

11/d


$p < 0.05$  Impact vs. Control





# Risposta metabolica: IMN vs. Std


## Microperfusion (Laser-Doppler)




\* p<0,05

(Braga, Arch Surg, 1996)

## IL-1 R II (pg/mL)




## IL-6 (pg/mL)



# Postsurgical Infections are Reduced with Specialized Nutrition Support

Dan L. Waitzberg, MD,<sup>1</sup> Hideaki Saito, MD,<sup>2</sup> Lindsay D. Plank, PhD,<sup>3</sup>




16 studi clinici

## Autore

- Amsterdam study (pre-op Group1) \*
- Amsterdam study (pre-op Group2) \*
- Gianotti et al 2002 (pre-op)
- Braga et al 2002 (pre-op)
- Braga et al 2001 (pre-op)
- Tepaske et al 2001 (pre-op)
- McCarter et al 1998 (pre-op)
- Sydney study (peri-op) \*
- Beme study (peri-op Group2) \*
- Beme study (peri-op Group1) \*
- Braga et al 2002 (peri-op)
- Gianotti et al 2002 (peri-op)
- Braga et al 2002 (peri-op)
- Braga et al 1999 (peri-op)
- Snyderman et al 1999 (peri-op)
- Senkal et al 1999 (peri-op)

Effetto combinato



# Conclusions

- Ageing is characterized by immunosenescence and progressive decline in immunity;
- This complex process affects both innate and immune system
- Nutritional interventions have shown some promising results in targeting some of the impairments of the immune system observed with aging;
- Which molecular pathways of chronic inflammation (inflammaging) can be effectively targeted by a nutritional approach still needs to be determined;



# Dieta mediterranea



<p>Characterized by dietary patterns found in olive-growing regions of the Mediterranean: high consumption of olive oil, vegetable, fruits, nuts and cereals. Moderate intake of fish, poultry. Low intake of dairy product, red and processed meat (Gonzalez, 2000).</p>	Osler 1997; Lasheras 2000; Trichopoulou 2003	MD	Association with a significant and substantial reduction in overall mortality
	Carluccio 2003; Cortes 2006; Dell'Agli 2006	Olive oil consumption in patients at risk of coronary heart disease	<p>Reduced expression of ICAM-1, VCAM-1, and E-selectins</p> <p>Decrease plasma concentration of sICAM-1, sVCAM-1, sE-selectin, IL-6, and CRP</p>
	Tangney 2011 Valls-Pedret 2012; Feart 2009 Scarmeas 2009	MD	Improved cognitive performances in dementia patients. MD associated with slower cognitive decline, reduction of mild cognitive impairment, reduction of neurodegenerative disorders such as Parkinson and Alzheimer
	Azzini 2011	MD	MD associated with down-regulation of CD49d and CD40 expression in monocytes. Reduced plasma expression of inflammatory markers such as sICAM-1, svCAM-1, CRP, IL-6, TNF $\alpha$ , IL-12. Higher levels of anti-inflammatory cytokine IL-10

Larbi A et al. Nutrition as a tool to reverse immunosenescence? In Immunity and inflammation in health disease, 2018